Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Research: CREBBP mutation may help cancer resist steroid treatment, fuel ALL's return

Research: CREBBP mutation may help cancer resist steroid treatment, fuel ALL's return

Caltech students receive Lemelson-MIT Prize for innovative disease diagnostic technology works

Caltech students receive Lemelson-MIT Prize for innovative disease diagnostic technology works

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Experimental drug effectively shuts off MCL1 gene and induces apoptosis

Novel sortase-based techniques allow modification of a large variety of different proteins

Novel sortase-based techniques allow modification of a large variety of different proteins

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

Fluidigm fourth quarter revenue increases to $10.4 million

Fluidigm fourth quarter revenue increases to $10.4 million

NHMRC awards $38.4M for cancer and blood cell research

NHMRC awards $38.4M for cancer and blood cell research

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

North Shore-LIJ launches new prenatal quality initiative

North Shore-LIJ launches new prenatal quality initiative

CBAI modifies authorized shares from pro-rata 500 to 250 million

CBAI modifies authorized shares from pro-rata 500 to 250 million

Cancer patients' willingness to undergo tests bodes well for future of personalized medicine

Cancer patients' willingness to undergo tests bodes well for future of personalized medicine

New study finds liver instead of the brain as source of Alzheimer’s plaques

New study finds liver instead of the brain as source of Alzheimer’s plaques

BioSante vaccine increases median survival of resected pancreatic cancer patients

BioSante vaccine increases median survival of resected pancreatic cancer patients

EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

EpiCept: Positive outcome from Ceplene Phase III trial in patients with AML

New microfluidic device may help clinicians to improve cancer therapy

New microfluidic device may help clinicians to improve cancer therapy

Cord Blood America purchases all UCB samples and related lab equipment from RGI

Cord Blood America purchases all UCB samples and related lab equipment from RGI

Mathematical model predicts lifespan of stem cells

Mathematical model predicts lifespan of stem cells

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.